| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 临床研究服务(元) | 113,036,184.21 | 303,671,717.70 | 143,299,923.14 | 243,686,889.98 | 109,967,666.56 |
| 药学研究服务(元) | 13,629,778.46 | 38,521,023.59 | 18,109,288.88 | 60,452,446.00 | 28,093,708.42 |
| 研发技术成果转化(元) | 17,901,886.79 | - | 18,079,547.16 | - | - |
| 其他(元) | 2,270,361.10 | 36,897,964.70 | 7,725,796.68 | 37,667,196.87 | 13,181,566.86 |
| 营业成本(元) | |||||
| 临床研究服务(元) | 79,526,441.78 | 191,090,097.29 | 86,059,684.98 | 145,614,775.70 | 61,729,109.39 |
| 药学研究服务(元) | 10,962,769.90 | 20,528,534.58 | 9,406,798.36 | 21,114,901.98 | 9,212,107.50 |
| 研发技术成果转化(元) | 786,865.79 | - | 747,564.63 | - | - |
| 其他(元) | 4,570,369.32 | 17,432,111.78 | 4,677,493.72 | 7,804,123.84 | 7,595,278.03 |
| 毛利(元) | |||||
| 临床研究服务(元) | 33,509,742.43 | 112,581,620.41 | 57,240,238.16 | 98,072,114.28 | 48,238,557.17 |
| 药学研究服务(元) | 2,667,008.56 | 17,992,489.01 | 8,702,490.52 | 39,337,544.02 | 18,881,600.92 |
| 研发技术成果转化(元) | 17,115,021.00 | - | 17,331,982.53 | - | - |
| 其他(元) | -2,300,008.22 | 19,465,852.92 | 3,048,302.96 | 29,863,073.03 | 5,586,288.83 |
| 毛利率(%) | |||||
| 临床研究服务(%) | 29.65 | 37.07 | 39.94 | 40.25 | 43.87 |
| 药学研究服务(%) | 19.57 | 46.71 | 48.06 | 65.07 | 67.21 |
| 研发技术成果转化(%) | 95.60 | - | 95.87 | - | - |
| 其他(%) | -101.31 | 52.76 | 39.46 | 79.28 | 42.38 |
| 收入构成(%) | |||||
| 临床研究服务(%) | 76.98 | 80.11 | 76.54 | 71.29 | 72.71 |
| 药学研究服务(%) | 9.28 | 10.16 | 9.67 | 17.69 | 18.58 |
| 研发技术成果转化(%) | 12.19 | - | 9.66 | - | - |
| 其他(%) | 1.55 | 9.73 | 4.13 | 11.02 | 8.72 |
| 毛利构成(%) | |||||
| 临床研究服务(%) | 65.72 | 75.03 | 66.31 | 58.63 | 66.35 |
| 药学研究服务(%) | 5.23 | 11.99 | 10.08 | 23.52 | 25.97 |
| 研发技术成果转化(%) | 33.56 | - | 20.08 | - | - |
| 其他(%) | -4.51 | 12.97 | 3.53 | 17.85 | 7.68 |